AR049353A1 - Derivados de acido carboxilico de bencimidazolona como agonistas del receptor 5-ht4; composiciones farmaceuticas que los comprenden como principio activo e intermediarios utiles en su preparacion. - Google Patents
Derivados de acido carboxilico de bencimidazolona como agonistas del receptor 5-ht4; composiciones farmaceuticas que los comprenden como principio activo e intermediarios utiles en su preparacion.Info
- Publication number
- AR049353A1 AR049353A1 ARP050102433A ARP050102433A AR049353A1 AR 049353 A1 AR049353 A1 AR 049353A1 AR P050102433 A ARP050102433 A AR P050102433A AR P050102433 A ARP050102433 A AR P050102433A AR 049353 A1 AR049353 A1 AR 049353A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- atom
- disease
- alkyl
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composiciones que contienen tales compuestos y el uso de tales compuestos en el tratamiento de una afeccion mediada por la actividad del receptor 5-HT4 tal como, pero sin limitacion a, enfermedad de reflujo gastroesofágico, enfermedad gastrointestinal, trastorno de motilidad gástrica, dispepsia no ulcerosa, dispepsia funcional, síndrome de intestino irritable (IBS), estrenimiento, dispepsia, esofagitis, enfermedad gastroesofágica, náuseas, enfermedad del sistema nervioso central, enfermedad de Alzheimer, trastorno cognitivo, emesis, migrana, enfermedad neurologica, dolor, trastornos cardiovasculares, tales como insuficiencia cardíaca y arritmia cardíaca, diabetes y síndrome de apnea. Reivindiacion 1: Un compuesto de formula (1) o una sal o solvato farmacéuticamente aceptable del mismo, en la que: A es un grupo alquileno C1-4, estando dicho grupo alquileno no substituido o substituido con 1 a 4 substituyentes seleccionados independientemente entre el grupo constituido por un átomo de halogeno, un grupo alquilo C1-4, un grupo hidroxi, -alquilo C1-4 y un grupo alxcoxi-alquilo C2-6, en el que dos sustituyentes cualquiera no halogeno se pueden tomar junto con los átomos de C a los que están unidos para formar un anillo de 3 a 6 miembros que opcionalmente contiene al menos un heteroátomo seleccionado entre N, O, y S; R1 es un grupo isopropilo o un grupo ciclopentilo; R2 es un átomo de H, un átomo de halogeno o un grupo hidroxi; R3 es un grupo carboxi, un grupo tetrazolilo, un grupo 5-oxo-1,2,4-oxadiazol-3-ilo o un grupo 5-oxo-1,2,4-tiadiazol-3-ilo; y m es un numero entero 1 o 2. Reivindicacion 11: Un compuesto de formula (2) o una sal del mismo, en la que: R2 es un átomo e H, un grupo hidroxi o un átomo de halogeno; R6 es un átomo de H o un grupo proyector de amino; Y es un grupo alcoxi que tiene entre 1 y 4 átomos de C, un grupo dialquilamino que tiene entre 2 y 8 átomos de C, un grupo imidazolilo, un grupo ftalimidilo, grupo succinimidilo o grupo sulfonilo; y m es 1 o 2. Reivindicacion 12: Un compuesto de formula (3) o una sal del mismo, en la que: A es un grupo alquileno C1-4, estando dicho grupo alquileno no sustituido o sustituido con 1 a 4 sustituyentes seleccionados independientemente entre el grupo constituido por un átomo de halogeno, un grupo alquilo C1-4, un grupo hidroxi-alquilo C1-4 y un grupo alcoxi-alquilo C2-6, en el que 2 sustituyentes no halogeno cualquiera se pueden tomar juntos con los átomos de C a los que están unidos para formar un anillo de 3 a 6 miembros que opcionalmente contiene al menos un heteroátomo seleccionado entre N, O y S; R2 es un átomo de H, un grupo hidroxi o un átomo de halogeno; R4 es un grupo hidroxi o un grupo protector de carboxi; R6 es un átomo de H o un grupo protector de amino; y m es 1 o 2.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004177488A JP4129445B2 (ja) | 2004-06-15 | 2004-06-15 | ベンズイミダゾロンカルボン酸誘導体 |
US60703504P | 2004-09-02 | 2004-09-02 | |
US60704804P | 2004-09-02 | 2004-09-02 | |
US60700804P | 2004-09-02 | 2004-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR049353A1 true AR049353A1 (es) | 2006-07-19 |
Family
ID=35414645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102433A AR049353A1 (es) | 2004-06-15 | 2005-06-14 | Derivados de acido carboxilico de bencimidazolona como agonistas del receptor 5-ht4; composiciones farmaceuticas que los comprenden como principio activo e intermediarios utiles en su preparacion. |
Country Status (24)
Country | Link |
---|---|
US (3) | US7705020B2 (es) |
EP (1) | EP1758891A2 (es) |
KR (1) | KR100875558B1 (es) |
AR (1) | AR049353A1 (es) |
AU (1) | AU2005254800B2 (es) |
BR (1) | BRPI0512046A (es) |
CA (1) | CA2569654C (es) |
CR (1) | CR8756A (es) |
EA (3) | EA200801608A1 (es) |
EC (1) | ECSP067079A (es) |
GE (1) | GEP20094638B (es) |
GT (1) | GT200500156A (es) |
HK (1) | HK1104031A1 (es) |
IL (1) | IL179612A (es) |
MA (1) | MA28667B1 (es) |
MX (1) | MXPA06014486A (es) |
NL (1) | NL1029250C2 (es) |
NO (1) | NO20065160L (es) |
PA (1) | PA8636901A1 (es) |
PE (1) | PE20060298A1 (es) |
SV (1) | SV2008002145A (es) |
TW (1) | TWI298635B (es) |
UY (1) | UY28961A1 (es) |
WO (1) | WO2005123718A2 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL189872B1 (pl) | 1996-07-24 | 2005-10-31 | Warner Lambert Co | Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu |
ATE539077T1 (de) * | 2003-09-03 | 2012-01-15 | Pfizer | Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor |
EP1758891A2 (en) * | 2004-06-15 | 2007-03-07 | Pfizer Japan Inc. | Benzimidazolone carboxylic acid derivatives |
JP5042028B2 (ja) | 2004-11-05 | 2012-10-03 | セラヴァンス, インコーポレーテッド | キノリノン−カルボキサミド化合物 |
ES2332808T3 (es) * | 2004-11-05 | 2010-02-12 | Theravance, Inc. | Compuestos agonistas del receptor 5-ht4. |
US7419989B2 (en) * | 2004-12-22 | 2008-09-02 | Theravance, Inc. | Indazole-carboxamide compounds |
JP4130220B1 (ja) * | 2005-02-22 | 2008-08-06 | ファイザー株式会社 | 5ht4受容体アゴニストとしてのオキシインドール誘導体 |
BRPI0608392A2 (pt) * | 2005-03-02 | 2009-12-29 | Theravance Inc | compostos de quinolinona como agonistas do receptor 5-ht4 |
DE602006019213D1 (de) * | 2005-03-15 | 2011-02-10 | Pfizer | Benzimidazolonderivate als cb2-rezeptor-liganden |
AU2006262101A1 (en) * | 2005-06-23 | 2007-01-04 | Merck & Co., Inc. | 3-fluoro-piperidine T-type calcium channel antagonists |
AU2006263564A1 (en) * | 2005-06-29 | 2007-01-04 | Merck Sharp & Dohme Corp. | 4-fluoro-piperidine T-type calcium channel antagonists |
GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
MX2008009652A (es) * | 2006-01-24 | 2008-11-06 | R Tech Ueno Ltd | Composicion farmaceutica que comprende un compuesto biciclico y metodo para estabilizar el compuesto biciclico. |
JP2010503654A (ja) * | 2006-09-12 | 2010-02-04 | ファイザー・プロダクツ・インク | ベンゾイミダゾロン誘導体 |
CA2667682A1 (en) | 2006-10-27 | 2008-05-15 | The Curators Of The University Of Missouri | Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same |
CA2716367C (en) | 2008-02-20 | 2015-05-26 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
EP2533780B1 (en) | 2010-02-12 | 2017-08-23 | AskAt Inc. | 5-ht4 receptor agonists for the treatment of dementia |
AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
AU2013255458A1 (en) | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH566987A5 (es) | 1972-04-21 | 1975-09-30 | Ciba Geigy Ag | |
US3945953A (en) * | 1972-04-21 | 1976-03-23 | Ciba-Geigy Corporation | ω,ω'-Bis-[4-amino-3-aminomethyl-piperidyl-(1)]-alkanes, process for their manufacture and their use |
JPS5965073A (ja) | 1982-10-05 | 1984-04-13 | Kowa Co | インド−ル誘導体 |
DE3336024A1 (de) | 1983-10-04 | 1985-04-18 | Boehringer Ingelheim KG, 6507 Ingelheim | 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel |
US5193547A (en) * | 1984-07-16 | 1993-03-16 | Evans Ii George D | Universal connector means for transducer/monitor systems |
US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
US5552408A (en) * | 1987-09-23 | 1996-09-03 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists |
US5223511A (en) | 1987-09-23 | 1993-06-29 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists |
JP2643274B2 (ja) | 1988-04-08 | 1997-08-20 | 三菱化学株式会社 | イミダゾ〔1,2−a〕ピリジン誘導体 |
GB8829079D0 (en) | 1988-12-13 | 1989-01-25 | Beecham Group Plc | Novel compounds |
EP0407217A1 (en) | 1989-07-07 | 1991-01-09 | Schering Corporation | Pharmaceutically active compounds |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9009389D0 (en) | 1990-04-26 | 1990-06-20 | Smith Kline French Lab | Treatment |
GB9020927D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Pharmaceuticals |
JPH06506443A (ja) | 1991-01-09 | 1994-07-21 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アザ二環式およびアザ三環式誘導体、その製法および中間体ならびに該化合物含有の医薬組成物 |
US5196547A (en) | 1991-03-07 | 1993-03-23 | G. D. Searle & Co. | Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
US5260303A (en) * | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
US5219850A (en) | 1991-03-07 | 1993-06-15 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
US5137893A (en) | 1991-03-07 | 1992-08-11 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
US5955470A (en) * | 1991-06-11 | 1999-09-21 | Merrell Pharmaceuticals, Inc. | Derivatives of amide analogs of certain methano bridged quinolizines |
EP0522914A1 (fr) * | 1991-06-27 | 1993-01-13 | Synthelabo | Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique |
IT1251144B (it) | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
GB9121170D0 (en) | 1991-10-05 | 1991-11-20 | Smithkline Beecham Plc | Pharmaceuticals |
GB9121835D0 (en) | 1991-10-15 | 1991-11-27 | Smithkline Beecham Plc | Pharmaceuticals |
GB9204565D0 (en) * | 1992-03-03 | 1992-04-15 | Smithkline Beecham Plc | Pharmaceuticals |
US5300512A (en) * | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
US5280028A (en) * | 1992-06-24 | 1994-01-18 | G. D. Searle & Co. | Benzimidazole compounds |
US5521193A (en) | 1992-06-24 | 1996-05-28 | G. D. Searle & Co. | Benzimidazole compounds |
FR2694292B1 (fr) | 1992-07-29 | 1994-10-21 | Esteve Labor Dr | Dérivés de benzimidazole-2-thione-, leur préparation et leur application en tant que médicament. |
MX9305947A (es) | 1992-09-29 | 1994-06-30 | Smithkline Beecham Plc | Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. |
GB9221468D0 (en) | 1992-10-13 | 1992-11-25 | Smithkline Beecham Plc | Pharmaceuticals |
KR950704328A (ko) | 1992-11-05 | 1995-11-17 | 데이비드 로버츠 | 5-HT₄ 수용체 길항제로서의 피페리딘 유도체(Piperidine Derivatives as 5-HT₄ Receptor Antagonists) |
TW251287B (es) | 1993-04-30 | 1995-07-11 | Nissei Co Ltd | |
GB9312348D0 (en) | 1993-06-16 | 1993-07-28 | Smithkline Beecham Plc | Pharmaceuticals |
US5534521A (en) * | 1993-06-23 | 1996-07-09 | G. D. Searle & Co. | Benzimidazole compounds |
CA2134192A1 (en) | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
US5399562A (en) | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
US5864039A (en) * | 1994-03-30 | 1999-01-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and use thereof as medicaments |
GB9414139D0 (en) | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Novel compounds |
WO1996005166A1 (fr) | 1994-08-11 | 1996-02-22 | Yamanouchi Pharmaceutical Co., Ltd. | Derive d'amine substitue et composition medicamenteuse le contenant |
IT1275903B1 (it) | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
SK282335B6 (sk) | 1995-11-09 | 2002-01-07 | Sanofi-Synthelabo | Deriváty 5-fenyl-3-(piperidin-4-yl)-1,3,4,-oxadiazol-2(3H)-ónu, spôsob ich prípravy a farmaceutický prostriedok, ktorý ich obsahuje |
JP2000504014A (ja) | 1996-01-30 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
US5968965A (en) | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU715202B2 (en) | 1996-04-03 | 2000-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
JPH10203987A (ja) | 1997-01-28 | 1998-08-04 | Dainippon Pharmaceut Co Ltd | (r)−1−エチル−4−メチルヘキサヒドロ−1h−1,4−ジアゼピン誘導体を有効成分とするモルヒネ様薬剤誘発嘔吐抑制剤 |
FR2762316B1 (fr) | 1997-04-18 | 1999-12-17 | Sanofi Synthelabo | Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
AU9309898A (en) * | 1997-09-09 | 1999-03-29 | Du Pont Pharmaceuticals Company | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa |
US6069152A (en) * | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
WO1999050264A1 (fr) | 1998-03-30 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Derives de quinazoline |
CN1303376A (zh) | 1998-03-31 | 2001-07-11 | 阿卡蒂亚药品公司 | 对毒蕈碱性受体具有活性的化合物 |
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
US6310059B1 (en) | 1998-06-30 | 2001-10-30 | Neuromed Technologies, Inc. | Fused ring calcium channel blockers |
US6492375B2 (en) | 1998-06-30 | 2002-12-10 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
CA2348267A1 (en) | 1998-10-29 | 2000-05-11 | Henry H. Gu | Novel inhibitors of impdh enzyme |
US6420410B1 (en) * | 1998-11-24 | 2002-07-16 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones |
TW570920B (en) | 1998-12-22 | 2004-01-11 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
JP4032566B2 (ja) | 1999-06-21 | 2008-01-16 | 東レ株式会社 | 発光素子 |
AU6936500A (en) | 1999-08-24 | 2001-03-19 | Regents Of The University Of California, The | Non-quinoline inhibitors of malaria parasites |
CA2397681C (en) | 1999-12-20 | 2011-03-15 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
FR2805815B1 (fr) | 2000-03-01 | 2002-05-17 | Sanofi Synthelabo | Derives de polyfluoroalkylimidazole, leur preparation et leur application en therapeutique |
WO2002018379A2 (en) * | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7-oxo pyridopyrimidines |
US20020128232A1 (en) | 2000-10-12 | 2002-09-12 | Henderson Scott A. | Heterocyclic angiogenesis inhibitors |
EP1341773A2 (en) * | 2000-12-07 | 2003-09-10 | Cv Therapeutics, Inc. | Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
US20040063716A1 (en) * | 2000-12-28 | 2004-04-01 | Hidemitsu Nishida | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds |
US6624162B2 (en) * | 2001-10-22 | 2003-09-23 | Pfizer Inc. | Imidazopyridine compounds as 5-HT4 receptor modulators |
MXPA03000145A (es) * | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
BR0314584A (pt) * | 2002-09-20 | 2005-08-09 | Pfizer | Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4 |
ITMI20030287A1 (it) * | 2003-02-18 | 2004-08-19 | Acraf | Indazolammidi dotate di attivita' analgesica metodo, per |
JP4671123B2 (ja) | 2003-06-23 | 2011-04-13 | 小野薬品工業株式会社 | 新規三環性複素環化合物 |
ATE539077T1 (de) | 2003-09-03 | 2012-01-15 | Pfizer | Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor |
US7737163B2 (en) * | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
EP1758891A2 (en) | 2004-06-15 | 2007-03-07 | Pfizer Japan Inc. | Benzimidazolone carboxylic acid derivatives |
-
2005
- 2005-06-01 EP EP05750293A patent/EP1758891A2/en not_active Withdrawn
- 2005-06-01 WO PCT/IB2005/001825 patent/WO2005123718A2/en active Application Filing
- 2005-06-01 AU AU2005254800A patent/AU2005254800B2/en not_active Ceased
- 2005-06-01 BR BRPI0512046-2A patent/BRPI0512046A/pt not_active IP Right Cessation
- 2005-06-01 EA EA200801608A patent/EA200801608A1/xx unknown
- 2005-06-01 MX MXPA06014486A patent/MXPA06014486A/es active IP Right Grant
- 2005-06-01 GE GEAP20059755A patent/GEP20094638B/en unknown
- 2005-06-01 EA EA200602122A patent/EA010891B9/ru not_active IP Right Cessation
- 2005-06-01 EA EA200801607A patent/EA200801607A1/xx unknown
- 2005-06-01 KR KR1020067026378A patent/KR100875558B1/ko not_active IP Right Cessation
- 2005-06-01 CA CA2569654A patent/CA2569654C/en not_active Expired - Fee Related
- 2005-06-13 PE PE2005000671A patent/PE20060298A1/es not_active Application Discontinuation
- 2005-06-14 UY UY28961A patent/UY28961A1/es not_active Application Discontinuation
- 2005-06-14 AR ARP050102433A patent/AR049353A1/es not_active Application Discontinuation
- 2005-06-14 US US11/153,775 patent/US7705020B2/en not_active Expired - Fee Related
- 2005-06-14 NL NL1029250A patent/NL1029250C2/nl not_active IP Right Cessation
- 2005-06-14 TW TW094119692A patent/TWI298635B/zh not_active IP Right Cessation
- 2005-06-14 US US11/153,757 patent/US7595329B2/en not_active Expired - Fee Related
- 2005-06-15 SV SV2005002145A patent/SV2008002145A/es unknown
- 2005-06-15 PA PA20058636901A patent/PA8636901A1/es unknown
- 2005-06-15 GT GT200500156A patent/GT200500156A/es unknown
-
2006
- 2006-11-09 NO NO20065160A patent/NO20065160L/no not_active Application Discontinuation
- 2006-11-20 CR CR8756A patent/CR8756A/es unknown
- 2006-11-27 IL IL179612A patent/IL179612A/en not_active IP Right Cessation
- 2006-12-13 EC EC2006007079A patent/ECSP067079A/es unknown
- 2006-12-15 MA MA29536A patent/MA28667B1/fr unknown
-
2007
- 2007-07-27 HK HK07108217.3A patent/HK1104031A1/xx not_active IP Right Cessation
-
2008
- 2008-01-09 US US11/971,265 patent/US20080108660A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049353A1 (es) | Derivados de acido carboxilico de bencimidazolona como agonistas del receptor 5-ht4; composiciones farmaceuticas que los comprenden como principio activo e intermediarios utiles en su preparacion. | |
AR053548A1 (es) | Derivados de oxiindol | |
JP6716785B2 (ja) | Hivウイルス感染症の予防的または治療的処置に有用な治療用化合物 | |
ES2916426T3 (es) | Formas sólidas de un inhibidor de la cápside del VIH | |
ES2705709T3 (es) | Compuestos de isoquinolina para el tratamiento del VIH | |
RU2448096C2 (ru) | Диарилгидантоины | |
RU2737190C2 (ru) | Ингибиторы репликации вируса гриппа, способы их применения и использование | |
CA2615611A1 (en) | Indazole derivatives | |
RU2339637C1 (ru) | Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием | |
ES2569677T3 (es) | Compuestos bicicloheteroarilo como moduladores de P2X7 y usos de los mismos | |
AR045552A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
ES2606043T3 (es) | Derivados de biarilo como moduladores de nAChR | |
WO2006090817A1 (ja) | インドール化合物およびその用途 | |
ES2576643T3 (es) | Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos | |
HUE035462T2 (en) | Bicyclic substituted uracil derivatives and their use | |
BRPI0713253A2 (pt) | método de inibição de pde4, método de tratamento de um doença mediada por pde4, composto e composição farmacêutica | |
AR055015A1 (es) | Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos. | |
CN102656164A (zh) | 作为结核病抑制剂的嘧啶化合物 | |
AR060914A1 (es) | Derivados de furopiridina como ligandos receptores de la acetilcolina nicotinica, una composicion farmaceutica que los comprende y su empleo en la manufactura de un medicamento para el tratamiento de una enfermedad mediada por la activacion del receptor alfa7-nicotinico. | |
EA200870448A1 (ru) | Тризамещенные 1,2,4-триазолы | |
AR071222A1 (es) | Compuestos heterociclicos espirocondensados | |
JP2006504621A (ja) | Hivプロテアーゼ阻害剤としてのカルバミン酸エステル | |
RU2001122727A (ru) | Амиды кислот, способ их получения и фармацевтическая композиция на их основе | |
ES2286230T3 (es) | Compuesto de n-fenilarilsulfonamida, medicamento que contiene el compuesto como principio activo intermedio para el compuesto y procedimiento para producirlos. | |
KR20170081228A (ko) | 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |